Skip to content
HomeMedia CenterPress releases Medical technologiesFDA Clears Integration Between LifeScan’s OneTouch Verio Flex® Blood Glucose Monitoring System and WellDoc’s BlueStar® Diabetes Management Platform

FDA Clears Integration Between LifeScan’s OneTouch Verio Flex® Blood Glucose Monitoring System and WellDoc’s BlueStar® Diabetes Management Platform

New connectivity highlights company’s commitment to creating an integrated, connected experience for people with diabetes and value for health care providers

Share Article
share to
One Touch Verio

December 13, 2016, Chesterbrook, PALifeScan, Inc., part of the Johnson & Johnson Diabetes Care Companies and a world leader in blood glucose monitoring, today announced the U.S. Food and Drug Administration (FDA) has cleared the wireless integration of the OneTouch Verio Flex® blood glucose monitoring system with WellDoc Inc.’s clinically validated diabetes management platform, BlueStar®, creating a unique digital health solution for people living with Type 2 diabetes.

Using blood glucose data wirelessly and automatically transmitted from the OneTouch Verio Flex® blood glucose monitoring system with built-in Bluetooth®[i] Smart Technology, WellDoc Inc.’s patented clinical and behavioral engine will provide patients with individualized real-time feedback and virtual coaching based on the patient’s specific treatment plan, and also help health care teams make timely diabetes management decisions. Along with the OneTouch Reveal® web and mobile app, the offering seeks to create a comprehensive, data-driven and payer-reimbursed program for the management of Type 2 diabetes.

“Our partnership with WellDoc highlights our sustained commitment in helping to drive better health outcomes by building a more connected patient experience. Integrating digital solutions such as OneTouch Reveal® mobile app and BlueStar® will help patients self-manage their diabetes and create value for health care providers.” said Valerie Asbury, World Wide President, LifeScan, Inc.

LifeScan’s OneTouch Verio Flex® meter with BlueTooth® Smart Technology features ColorSure™ technology, and is a simple, accurate and easy-to-use meter that takes the guesswork out of blood sugar test results for people with diabetes. The OneTouch Verio Flex® meter also has optional wireless connectivity with the OneTouch Reveal® mobile app to help patients manage their diabetes. WellDoc’s BlueStar® is a digital therapeutic platform cleared by the U.S. Food and Drug Administration for adults with Type 2 diabetes.

LifeScan and WellDoc are currently working with health plans to help provide patient access for this integrated system. People with diabetes and their caregivers who are interested can ask their health plans and healthcare providers for information on integrating their OneTouch Verio Flex® blood glucose monitoring system with BlueStar®.

About Johnson & Johnson Diabetes Care Companies (JJDCC)
With a shared vision of creating a world without limits for people with diabetes, the Johnson & Johnson Diabetes Care Companies are a collaboration of Johnson & Johnson companies dedicated to diabetes and includes LifeScan, Inc., a world leader in blood glucose monitoring; Animas Corporation, maker of innovative insulin delivery systems; Calibra Medical, Inc. developer of OneTouch Via™ on-demand insulin delivery; and the Johnson & Johnson Diabetes Institute, LLC, a global initiative to improve care and better outcomes worldwide through education and training programs. In the U.S., Lifescan, Inc. is the leading blood glucose monitoring company and OneTouch® brand products are recommended by more endocrinologists and primary care physicians than any other brand[1]. Globally, more than 15 million people depend on OneTouch® brand products to help them manage their diabetes. For more information, visit:

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the benefits of integrating OneTouch® products and BlueStar®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of LifeScan, Inc. or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Neither LifeScan, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.


Bridget Doherty


Investor Contact:

Lisa Romanko


[1] Global Brand Equity Insights Study, February 2015.

[i] The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by LifeScan Scotland Ltd. is under license. Other trademarks and trade names are those of their respective owners.

You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.